We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$958M
AUM Growth
+$3.46M
Cap. Flow
+$6.87M
Cap. Flow %
0.72%
Top 10 Hldgs %
27.27%
Holding
97
New
7
Increased
32
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.5M
2
MDT icon
Medtronic
MDT
+$8.92M
3
TECH icon
Bio-Techne
TECH
+$7.15M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.83M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.66M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$11M
3
UNH icon
UnitedHealth
UNH
+$8.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.62M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Industrials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$32.2M 3.36%
88,000
-9,000
-9% -$3.19M
COR icon
2
Cencora
COR
$60.6B
$28.7M 2.99%
173,000
+37,000
+27% +$5.85M
MDT icon
3
Medtronic
MDT
$109B
$27.2M 2.84%
350,000
+110,000
+46% +$8.92M
BSX icon
4
Boston Scientific
BSX
$69.5B
$27.1M 2.82%
585,000
-110,000
-16% -$4.76M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$26.7M 2.79%
37,000
+5,000
+16% +$3.69M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$26.3M 2.74%
254,000
+17,000
+7% +$1.6M
MRK icon
7
Merck
MRK
$322B
$23.9M 2.49%
215,000
– –
GILD icon
8
Gilead Sciences
GILD
$162B
$23.2M 2.42%
270,000
– –
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$23.1M 2.41%
80,000
-16,000
-17% -$4.88M
ELV icon
10
Elevance Health
ELV
$81.5B
$23.1M 2.41%
45,000
+5,000
+13% +$2.54M
THC icon
11
Tenet Healthcare
THC
$20.5B
$23M 2.4%
470,750
+126,750
+37% +$5.86M
TMO icon
12
Thermo Fisher Scientific
TMO
$213B
$22M 2.3%
40,000
-12,500
-24% -$6.62M
HCA icon
13
HCA Healthcare
HCA
$87.2B
$21.6M 2.25%
90,000
+47,000
+109% +$10.5M
BDX icon
14
Becton Dickinson
BDX
$45.6B
$21.1M 2.2%
83,000
-2,000
-2% -$472K
ABBV icon
15
AbbVie
ABBV
$443B
$21M 2.19%
130,000
-19,626
-13% -$3.01M
CI icon
16
Cigna
CI
$73.7B
$20.5M 2.14%
62,000
-13,000
-17% -$4.11M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.9B
$20.4M 2.13%
128,000
-3,500
-3% -$513K
UNH icon
18
UnitedHealth
UNH
$376B
$20.1M 2.1%
38,000
-16,800
-31% -$8.9M
HUM icon
19
Humana
HUM
$43.7B
$20M 2.08%
39,000
-5,000
-11% -$2.63M
PFE icon
20
Pfizer
PFE
$143B
$17.9M 1.87%
350,000
– –
JNJ icon
21
Johnson & Johnson
JNJ
$618B
$17.7M 1.84%
100,000
– –
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$27.5B
$17.3M 1.81%
73,000
-2,000
-3% -$427K
BNTX icon
23
BioNTech
BNTX
$22.9B
$16.4M 1.71%
109,000
+10,000
+10% +$1.54M
CVS icon
24
CVS Health
CVS
$133B
$15.9M 1.66%
171,000
-54,000
-24% -$5.21M
COO icon
25
Cooper Companies
COO
$14.1B
$15.5M 1.62%
188,000
+392
+0.2% +$28.9K
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rhenman & Partners Asset Management held 97 positions worth $958M, up 0.36% from $955M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q4 2022 filing shows 7 new, 32 increased, 18 reduced and 4 closed positions. Its largest new stake was Bio-Techne: 90,000 shares worth $7.46M. The largest sale was Abiomed Inc, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q4 2022 buy was Bio-Techne: 90,000 shares worth $7.46M.
  • Rhenman & Partners Asset Management added most to HCA Healthcare in Q4 2022, an estimated $10.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2022 reduction was Intuitive Surgical, cutting an estimated $11M.
  • Rhenman & Partners Asset Management fully exited Abiomed Inc in Q4 2022, selling an estimated $21.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $958M portfolio in Q4 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 4 in Q4 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 0.36% quarter-over-quarter to $958M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.